Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.51 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.51 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | KDM4C | Q9H3R0 | 5/20 | 0.51 |
| ▸ | KDM5B | Q9UGL1 | 3/20 | 0.51 |
| ▸ | KDM5A | P29375 | 2/20 | 0.51 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | KDM4A | O75164 | 2/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL325139 | 0.79 | LTA4H (0.59) | HPGDSCYP3A4CYP2D6CYP2E1CYP2A6 | |
| SCHEMBL13137743 | 0.76 | HPGDS (0.67) | HPGDSCYP3A4CYP2D6CYP2E1CYP2A6 | |
| SCHEMBL1346083 | 0.76 | HPGDS (0.77) | HPGDSCYP3A4CYP2D6CYP2E1CYP2A6 | |
| SCHEMBL2315630 | 0.72 | HPGDS (1.00) | HPGDSCYP3A4CYP2D6CYP2E1CYP2A6 | |
| SCHEMBL19925217 | 0.72 | HPGDS (0.53) | HPGDSCYP3A4CYP2D6CYP2E1CYP2A6 | |
| SCHEMBL28714930 | 0.71 | HPGDS (0.64) | HPGDSCYP3A4CYP2D6CYP2E1CYP2A6 | |
| SCHEMBL5758839 | 0.71 | HPGDS (0.59) | HPGDSCYP3A4CYP2D6CYP2E1CYP2A6 | |
| SCHEMBL25395574 | 0.70 | HPGDS (0.51) | HPGDSCYP3A4CYP2D6CYP2E1CYP2A6 | |
| SCHEMBL1196872 | 0.70 | HPGDS (0.51) | HPGDSCYP3A4CYP2D6CYP2E1CYP2A6 | |
| SCHEMBL2972635 | 0.70 | HPGDS (0.51) | HPGDSCYP3A4CYP2D6CYP2E1CYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7550471-B2 | 5-alkyl-7-aminotriazolopyrimidines, methods and intermediary product necessary for the production thereof, agents containing said compounds and the use thereof for fighting against harmful mushrooms | BASF AKTIENGESELLSCHAFT (DE) | 2009-06-23 | — | — | US | disclosed |
| US-7307172-B2 | 7-amino triazolopyrimidines for controlling harmful fungi | BASF AKTIENGESELLSCHAFT (DE) | 2007-12-11 | — | — | US | disclosed |
| CN-1318423-C | 7-amino-triazolopyrimidines for controlling harmful fungi | BASF AG (DE) | 2007-05-30 | — | — | CN | disclosed |
| EP-1414302-B1 | 7-AMINO TRIAZOLOPYRIMIDINES FOR CONTROLLING HARMFUL FUNGI | BASF AG (DE) | 2007-03-21 | — | — | EP | disclosed |
| EP-1585747-B1 | 5-ALKYL-7-AMINOTRIAZOLOPYRIMIDINES, METHODS AND INTERMEDIATES SUITABLE FOR THEIR PRODUCTION, AGENTS CONTAINING THEM AND THEIR USE FOR CONTROLLING HARMFUL FUNGI | BASF AG (DE) | 2006-09-13 | — | — | EP | disclosed |
| CN-1711263-A | 5-alkyl-7-aminotriazolopyrimidines, methods and intermediary product necessary for the production thereof, agents containing said compounds and the use thereof for fighting against harmful mushrooms | BASF AG (DE) | 2005-12-21 | — | — | CN | disclosed |
| US-20050272749-A1 | 5-Alkyl-7-aminotriazolopyrimidines, methods and intermediary product necessary for the production thereof, agents containing said compounds and the use thereof for fighting against harmful mushrooms | BASF AKTIENGESELLSCHAFT (DE) | 2005-12-08 | — | — | US | disclosed |
| US-20050261314-A1 | 7-Amino triazolopyrimidines for controlling harmful fungi | BASF AKTIENGESELLSCHAFT (DE) | 2005-11-24 | — | — | US | disclosed |
| EP-1585747-A1 | 5-ALKYL-7-AMINOTRIAZOLOPYRIMIDINES, METHODS AND INTERMEDIARY PRODUCTS NECESSARY FOR THE PRODUCTION THEREOF, AGENTS CONTAINING SAID COMPOUNDS AND THE USE THEREOF FOR FIGHTING AGAINST HARMFUL MUSHROOMS | BASF Aktiengesellschaft (DE) | 2005-10-19 | — | — | EP | disclosed |
| CN-1535113-A | 7-amino-triazolopyrimidines for controlling harmful fungi | �����ɷ� | 2004-10-06 | — | — | CN | disclosed |
| WO-2004041825-A1 | 5-ALKYL-7-AMINOTRIAZOLOPYRIMIDINES, METHODS AND INTERMEDIARY PRODUCTS NECESSARY FOR THE PRODUCTION THEREOF, AGENTS CONTAINING SAID COMPOUNDS AND THE USE THEREOF FOR FIGHTING AGAINST HARMFUL MUSHROOMS | BASF AKTIENGESELLSCHAFT (DE) | 2004-05-21 | — | — | WO | disclosed |
| EP-1414302-A1 | 7-AMINO TRIAZOLOPYRIMIDINES FOR CONTROLLING HARMFUL FUNGI | BASF AKTIENGESELLSCHAFT (DE) | 2004-05-06 | — | — | EP | disclosed |
| WO-2003009687-A1 | 7-AMINO TRIAZOLOPYRIMIDINES FOR CONTROLLING HARMFUL FUNGI | BASF AKTIENGESELLSCHAFT (DE) | 2003-02-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050272749-A1 | 5-Alkyl-7-aminotriazolopyrimidines, methods and intermediary product necessary for the production thereof, agents containing said compounds and the use thereof for fighting against harmful mushrooms | ERG28, CBR3, CBR1 | HPGDS 2746/4885CYP3A4 1288/4885CYP2D6 1695/4885 |
| US-20050261314-A1 | 7-Amino triazolopyrimidines for controlling harmful fungi | POLR1C, TYR, TH | HPGDS 3869/4885CYP3A4 725/4885CYP2D6 425/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.